The FDA has licensed 2026-2027 formulas of the mRNA COVID-19 vaccines Comirnaty, Spikevax, and mNEXSPIKE1 and the adjuvanted protein subunit COVID-19 vaccine Nuvaxovid.
The vaccines are FDA-licensed for use in adults ≥65 years old and in persons aged 6 months-64 years (Spikevax), 5-64 years (Comirnaty), or 12-64 years (mNEXSPIKE, Nuvaxovid) who are at high risk for severe COVID-19 because of an underlying condition.
THE NEW FORMULAS — The 2026-2027 COVID-19 vaccines are monovalent. They target the spike...
- Seasonal Influenza Vaccination: 2026-2027
- In Brief: A Cardiovascular Indication for Tirzepatide (Mounjaro)
- Gedatolisib (Revtorpyk) for Breast Cancer (online only)
- Lunsotogene Parvec (Otarmeni) for Hearing Loss (online only)
- Vusolimogene Oderparepvec (Tudriqev) – An Oncolytic Viral Therapy for Melanoma (online only)
RELEASE
The FDA has approved the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to reduce the urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) associated with type 1 diabetes. Reducing UACR is expected to reduce the risk of sustained eGFR decline and progression to end-stage kidney disease. Finerenone is the first drug to be approved in the US for this indication in 30 years.
OTHER INDICATIONS — Finerenone is also FDA-approved to reduce the risk of kidney disease progression and cardiovascular events in adults with CKD associated with type 2 diabetes and to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), and urgent HF visits in adults with HF with a left ventricular ejection fraction (LVEF) ≥40%.1,2
MECHANISM OF ACTION — CKD and cardiovascular disease are common complications of type 1 …